Vector-borne diseases (VBDs) represent a significant public health concern in India, with an increasing burden on the healthcare system. These diseases, transmitted by vectors like mosquitoes, ticks, and fleas, include malaria, dengue, chikungunya, and zika, among others. This article provides a comprehensive overview of the current challenges and potential strategies to address VBDs in India.
The Indian subcontinent's diverse climatic conditions and high population density create an ideal environment for the proliferation of vectors, leading to a high incidence of VBDs. Rapid urbanization, poor sanitation, and climate change further exacerbate the situation. According to the World Health Organization, India accounts for 89% of South-East Asia's malaria burden and 34% of dengue cases worldwide.
The primary challenges in addressing VBDs in India include inadequate surveillance, lack of public awareness, insufficient vector control measures, and limited access to healthcare services. Furthermore, the emergence of vector resistance to insecticides and pathogen resistance to drugs pose significant hurdles.
Effective VBD management necessitates a multi-pronged approach. Strengthening surveillance systems for early detection and prompt response, improving public health infrastructure, and enhancing community awareness are crucial. Additionally, integrated vector management strategies, including biological control measures and the judicious use of insecticides, are needed. Research and development in novel diagnostic tools, vaccines, and therapeutics should be prioritized.
The rising challenge of VBDs in India calls for concerted efforts from healthcare professionals, policymakers, researchers, and the community. While the task is daunting, adopting comprehensive, sustainable, and evidence-based strategies can significantly mitigate the impact of these diseases on public health. Continuing professional education and interdisciplinary collaboration will be key to navigating this complex landscape.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation